RHHBY
HealthcareRoche Holding AG · Drug Manufacturers - General · $321B
What is Roche Holding AG?
Roche Holding AG is a Swiss-headquartered global leader in both pharmaceuticals and diagnostics, operating across dozens of countries and serving patients in oncology, neuroscience, immunology, and beyond.
Roche generates revenue through two core divisions: pharmaceuticals and diagnostics. The pharma arm develops and markets treatments across oncology, immunology, ophthalmology, and neuroscience. The diagnostics division produces in vitro tests and instruments used to detect diseases including cancer, diabetes, and infectious conditions — making Roche one of the few companies that both treats and helps diagnose illness.
Roche was founded in 1896 and is headquartered in Basel, Switzerland.
- Oncology and immunology pharmaceuticals
- In vitro diagnostic tests and reagents
- Diagnostic instruments for clinical and laboratory use
- Treatments for neurological and ophthalmological conditions
Is RHHBY a Good Stock to Buy?
UQS Score rates RHHBY as Good overall, reflecting a balanced profile across the five quality pillars.
The Quality pillar stands out as the clearest strength, indicating a well-run business with durable financial characteristics. Valuation also registers as Good, suggesting the stock is not obviously expensive relative to its fundamentals.
Moat, Growth, and Risk all sit at Neutral, pointing to a competitive landscape where Roche faces meaningful pressure and near-term growth is not a standout factor.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does RHHBY pay dividends?
Yes — Roche Holding AG pays a dividend.
Roche pays a regular dividend, consistent with its long history as a mature, cash-generative pharmaceutical company. The dividend reflects management's commitment to returning capital to shareholders — a common trait among large, established European healthcare firms.
When does RHHBY report earnings?
Roche Holding reports earnings on a regular cadence, typical for internationally listed pharmaceutical companies.
Roche's dual-division structure means results are shaped by both drug sales trends and diagnostics volumes. Investors watch for pipeline updates and diagnostic demand as key indicators of underlying momentum.
For the most recent quarter's results, visit Roche Holding's official investor relations page.
RHHBY Price History
+23.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Roche Holding AG?
Based on Roche Holding AG's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Roche Holding do?
Roche Holding AG operates in two segments: pharmaceuticals and diagnostics. It develops treatments for oncology, neuroscience, and immunology while also producing diagnostic tests and instruments used to detect diseases like cancer, diabetes, and hepatitis.
Does RHHBY pay dividends?
Yes, Roche pays a regular dividend. As a mature, cash-generating pharmaceutical company headquartered in Switzerland, Roche has a long track record of returning capital to shareholders through consistent dividend payments.
When does RHHBY report earnings?
Roche reports on a regular cadence throughout the year. For exact dates and the most recent financial results, check Roche Holding's investor relations page directly.
Is RHHBY a good stock to buy?
UQS Score rates RHHBY as Good overall, with a particularly Strong Quality pillar. Whether it suits your portfolio depends on your goals. The full pillar breakdown — available to Pro members — provides a more complete picture.
Is RHHBY overvalued?
The UQS Valuation pillar for RHHBY is rated Good, suggesting the stock does not appear significantly overpriced relative to its fundamentals. View the complete valuation analysis by accessing the full UQS report.
What is RHHBY's market cap bracket?
Roche Holding is a mega-cap company, placing it among the largest publicly traded healthcare firms in the world by market value.
Is RHHBY a long-term quality stock?
The UQS framework evaluates long-term quality across five pillars. RHHBY's Strong Quality rating and Good overall score suggest a fundamentally sound business, though Neutral Moat and Growth ratings are worth monitoring over a longer horizon.
What sector does RHHBY belong to?
Roche Holding operates in the Healthcare sector, specifically spanning pharmaceutical drug development and in vitro diagnostics — two distinct but complementary areas within global healthcare.
Unlock Full RHHBY Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Moat, Growth, Risk, and Valuation
- ✓Access detailed financial metrics and peer comparisons
- ✓See how RHHBY ranks within the Healthcare sector
- ✓Get the complete analyst-style breakdown available to Pro members
Pro Analysis
RHHBY — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Jul 25, 2026 | 61.9 | 91.4 | 52.0 | 39.7 | 54.1 | 66.7 | 0.0 |
| Jul 24, 2026 | 61.9 | 89.1 | 52.0 | 40.2 | 55.9 | 68.2 | -0.3 |
| Jul 22, 2026 | 62.2 | 89.5 | 52.0 | 40.2 | 55.9 | 69.1 | +0.1 |
| Jul 21, 2026 | 62.1 | 89.6 | 52.0 | 40.2 | 55.9 | 68.8 | +0.1 |
| Jul 18, 2026 | 62.0 | 89.5 | 52.0 | 40.2 | 55.9 | 68.2 | -0.1 |
| Jul 17, 2026 | 62.1 | 89.6 | 52.0 | 40.2 | 55.9 | 68.5 | +0.2 |
| Jul 16, 2026 | 61.9 | 89.6 | 52.0 | 40.6 | 55.9 | 66.5 | -0.3 |
| Jul 15, 2026 | 62.2 | 89.7 | 52.0 | 40.6 | 55.9 | 68.8 | -0.1 |
| Jul 14, 2026 | 62.3 | 89.6 | 52.0 | 40.6 | 55.9 | 69.1 | +0.7 |
| Jul 12, 2026 | 61.6 | 89.4 | 52.0 | 40.5 | 55.9 | 65.3 | -0.1 |
RHHBY — Pillar Breakdown
Quality
— 91.4/100 (25%)Roche Holding AG demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 39.7/100 (20%)Roche Holding AG shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 54.1/100 (15%)Roche Holding AG has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 63.5/100 (15%)Roche Holding AG trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 52/100 (25%)Roche Holding AG possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for RHHBY.
Score Composition
Financial Data
More Stock Analysis
How is the RHHBY UQS Score Calculated?
The UQS (Unified Quality Score) for Roche Holding AG is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Roche Holding AG's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Roche Holding AG is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.